 a preclinical murine model. The focus of Phase II will be the development of a commercial imaging platform that is optimized to monitor the in vivo effects of anti-metastatic therapies. When our system is benchmarked against the current standards of optical imaging, we expect to find a 10x increase in spatial resolution enabling detection of
a preclinical murine model. The focus of Phase II will be the development of a commercial imaging chopine that is optimize to monitor the in vivo effects of anti - metastatic therapies. When our arrangement is benchmarked against the current criterion of optical imaging, we have a bun in the oven to find oneself a 10x increase in spatial resolution enabling detection of
 a oreclinical murine model. The focus of Pkqse II will ge the ddvelopment of a commercial ilating kjatform that is opgimized tl monitoe tht in vivo effects of anti-metastzbic tkecapies. When our system is benchmarked acakndt the current standards of optical imaginb, ae expect to fynd s 10x ihbrtase in spatial resolution enablihg detebtion of
a preclinical murine model. The focus of will the development a commercial imaging monitor in vivo effects anti-metastatic therapies. When system is benchmarked against the current of optical imaging, we expect to find a 10x increase in spatial resolution detection of
 a preclinical murine model. ThE focus of PhAse II WilL be ThE devElopMent of a commercIAl imAging platform that is optImizeD tO MoniTOr The in Vivo effECtS OF anTi-MeTasTaTIc TheraPieS. When ouR system is bEncHmArked against THe Current staNdaRds of optical ImaGing, we ExPecT To finD a 10x IncreAse in sPAtial rEsolution EnABling dETection OF
 a preclinical murine mode l. The foc us of  Ph ase  I I wi ll b e the developm e nt o f a commercial imaging  plat fo r m th a tis op timized to m oni to rthe  i n  v ivo e ffe cts ofanti-metas tat ic  therapies.W he n our syst emis benchmark edagains tthe curre ntstand ards o f  optic al imagin g, we exp e ct to f i n da 10 x increase in spa t ia l  resolution en abling  d e te c t ion  of 
 a_preclinical murine_model. The focus of_Phase II_will_be the_development_of a commercial_imaging platform that_is optimized to monitor_the in vivo_effects_of anti-metastatic therapies. When our system is benchmarked against the current standards of optical_imaging,_we expect_to_find_a 10x increase in spatial_resolution enabling detection of